World Health Organization Issues Alert Over Acute Lack of Obesity Injections

Less than a tenth of patients eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, warns the World Health Organization as it issues its inaugural recommendations on the drugs.

Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication.

Per forecasts, over two billion will be obese by 2030 if no action is taken.

"The latest guidance affirms that obesity is a lifelong illness that can be managed with thorough and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are major hurdles to universal access to the treatments that can help people shift considerable weight, explains the body.

Skinny Jab Scarcity

Even under the current most optimistic outlook, the production of these medications could only cover around 100 million people – under 10% of the global need, per the health organization.

The recommendation urges nations and manufacturers to expand availability, via approaches including licensing agreements.

The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.

The Way Obesity Drugs Operate

GLP-1 drugs mimick a body's own hormone to slow digestion, suppress the appetite and enhance feelings of fullness so users reduce food intake.

Individuals commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs.

Evidence suggests users may put most of the weight back on within a year of stopping the treatment, as their typical appetite resume.

Being above a healthy weight increases your chance for contracting health problems, such as diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight affects individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the health agency.